istock-487636172
marianvejcik / iStockphoto.com
20 October 2017Big Pharma

Alnylam faces declaratory relief claim over SPCs

Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates (SPCs) requested by biotech company Silence Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.

More on this story

Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.

More on this story

Americas
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
article
11 December 2018   UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Europe
7 July 2017   Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company.